SAT0293 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study

P Nash,A.J Kivitz,L Fallon,E Kudlacz,S Menon,T Hendrikx,L.C Coates,C Wang,D.D Gladman,P.J Mease,J.A Covarrubias-Cobos,K.S Kanik,D Fleishaker

doi:10.1136/annrheumdis-2018-eular.3115

SAT0293 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study

P Nash, A.J Kivitz + Show 11 more

Open Access

PDF Available

https://doi.org/10.1136/annrheumdis-2018-eular.3115

Copy DOI

Export

Save

Cite

Journal: Annals of the Rheumatic Diseases	Publication Date: Jun 1, 2018
Citations: 4

Affiliation: University of Queensland, Altoona Center for Clinical Research, Pfizer (Canada), Pfizer (United States)

#Pfizer Inc #Long-term Extension Study #Long-term Extension #Adverse Events #Efficacy Of Tofacitinib #OPAL Balance #Decrease In Absolute Lymphocyte Count #Efficacy Of Tofacitinib In Patients #Active Psoriatic Arthritis #Psoriatic Arthritis

Abstract
Full-Text PDF
Similar Papers

Abstract

Listen

BackgroundTofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA).ObjectivesTo report the safety, tolerability and efficacy of tofacitinib in patients (pts) with active PsA from an...

Full Text

Published Version (Free)

View/Download pdf

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of the Rheumatic Diseases

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

SAT0293 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study